THE AMERICAN SOCIETY OF GENE & CEL… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1996

Legal Domicile

Principal Officer

FEDERICO MINGOZZI PHD

Phone

4142781341

Tax Period

2024-01-01 to 2024-12-31

THE AMERICAN SOCIETY OF GENE & CELL THERAPY, founded in 1996, is a mid-sized nonprofit in the Medical Research sector that reported $16.9M in total revenue in fiscal year 2024. Expenses of $14.6M left a modest 14% surplus.

Mission

ASGCT'S MISSION IS TO ADVANCE KNOWLEDGE, AWARENESS, AND EDUCATION LEADING TO THE DISCOVERY AND CLINICAL APPLICATION OF GENETIC AND CELLULAR THERAPIES TO ALLEVIATE HUMAN DISEASE.

Program Service Accomplishments

Program 1

Expenses: $6,234,014 Revenue: $10,697,682

ANNUAL MEETING: THIS IS THE PRIMARY VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE ANNUAL MEETING REPRESENTS THE MAJOR EDUCATIONAL INITIATIVE OF THE SOCIETY.

Program 2

Expenses: $1,042,691 Revenue: $3,056,873

MOLECULAR THERAPY JOURNALS: PUBLISHING SCHOLARLY JOURNALS IS THE SECOND MAJOR VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE JOURNALS ARE THE WAY ASGCT EDUCATES AND UPDATES...

MOLECULAR THERAPY JOURNALS: PUBLISHING SCHOLARLY JOURNALS IS THE SECOND MAJOR VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE JOURNALS ARE THE WAY ASGCT EDUCATES AND UPDATES RESEARCHERS, CLINICIANS, AND STUDENTS ON THE LATEST ADVANCES IN THE DEVELOPMENT OF NOVEL THERAPEUTICS.

Program 3

Expenses: $850,215

ADVOCACY: ADVOCACY IS THE THIRD MAJOR VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE DEFINING VALUE OF ADVOCACY IS "GENE AND CELL THERAPY WILL HAVE A FINANCIAL IMPACT ON PATIENTS...

ADVOCACY: ADVOCACY IS THE THIRD MAJOR VEHICLE FOR CARRYING OUT THE EDUCATIONAL MISSION OF ASGCT. THE DEFINING VALUE OF ADVOCACY IS "GENE AND CELL THERAPY WILL HAVE A FINANCIAL IMPACT ON PATIENTS, PROVIDERS, AND PAYERS. ASGCT IS COMMITTED TO UNDERSTANDING THAT IMPACT AND EDUCATING DECISION-MAKERS ENGAGED IN DEVELOPING POLICIES THAT INFLUENCE PATIENT ACCESS TO TREATMENTS."

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $229,856

Program Service Revenue $15,624,301

Investment Income $1,024,374

Other Revenue $35,806

TOTAL REVENUE $16,914,337

Expense Breakdown

Grants Paid $1,266,770

Salaries & Benefits $5,250,736

Fundraising Expenses $822,860

Program Expenses $11,680,451

Other Expenses $8,061,620

TOTAL EXPENSES $14,579,126

Year-over-Year Comparison

	2024	2023	Change
Revenue	$16,914,337	$16,370,708	+0.0%
Expenses	$14,579,126	$13,754,627	+0.1%
Net Income	$2,335,211	$2,616,081	-0.1%

Key Indicators

✓ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$618,447

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JEFFREY S CHAMBERLAIN PHD	PAST PRESIDENT	5.00	Officer Director	$0	$0	$0
HANS-PETER KIEM MD PHD	PAST PRESIDENT	5.00	Officer Director	$0	$0	$0
PAULA CANNON PHD	PRESIDENT	5.00	Officer Director	$0	$0	$0
MATTHEW PORTEUS MD PHD	VICE PRESIDENT	5.00	Officer Director	$0	$0	$0
CLAIRE BOOTH MBBS PHD	PART YEAR DIRECTOR	3.00	Director	$0	$0	$0
KIMBERLY GOODSPEED MD	PART YEAR DIRECTOR	3.00	Director	$0	$0	$0
FEDERICO MINGOZZI PHD	TREASURER	5.00	Officer Director	$0	$0	$0
HILDEGARD BUNING PHD	PART YEAR DIRECTOR	3.00	Director	$0	$0	$0
MIGUEL SENA-ESTEVES PHD	PART YEAR DIRECTOR	3.00	Director	$0	$0	$0
MARIA-GRAZIA RONCAROLO MD	PART YEAR DIRECTOR	3.00	Director	$0	$0	$0
RAYNE H ROUCE MD	PART YEAR DIRECTOR	3.00	Director	$0	$0	$0
TERENCE R FLOTTE MD	PRESIDENT ELECT	5.00	Officer Director	$0	$0	$0
ISABELLE RIVIRE PHD	SECRETARY	5.00	Officer Director	$0	$0	$0
ARAVIND ASOKAN PHD	DIRECTOR	3.00	Director	$0	$0	$0
DANIEL E BAUER MD PHD	DIRECTOR	3.00	Director	$0	$0	$0
LINDSEY GEORGE MD	DIRECTOR	3.00	Director	$0	$0	$0
PUNAM MALIK MD	DIRECTOR	3.00	Director	$0	$0	$0
KAH-WHYE PENG PHD	DIRECTOR	3.00	Director	$0	$0	$0
JENNIFER WELLMAN MS	DIRECTOR	3.00	Director	$0	$0	$0
DAVID BARRETT	EXECUTIVE DIRECTOR	40.00	Officer	$577,778	$40,669	$618,447
MARGARITA LEA VALDEZ	EMPLOYEE	40.00	Highest	$242,394	$7,272	$249,666
RYAN HIETPAS	EMPLOYEE	40.00	Highest	$169,899	$14,949	$184,848
LAURA MICHELLE GALLAGHER	EMPLOYEE	40.00	Highest	$215,407	$15,816	$231,223
KELLIE BEUMER	EMPLOYEE	40.00	Highest	$153,501	$19,493	$172,994
JEAN NORTON	EMPLOYEE	40.00	Highest	$139,261	$24,148	$163,409

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$16,914,337	$14,579,126	$27,046,811	$2,335,211
2023	$16,370,708	$13,754,627	$23,810,378	$2,616,081
2022	$12,483,052	$10,958,628	$20,486,557	$1,524,424
2021	$8,934,604	$6,172,037	$15,452,389	$2,762,567
2020	$6,516,210	$4,511,431	$11,546,982	$2,004,779
2019	$6,509,265	$4,691,842	$9,695,835	$1,817,423
2018	$4,930,268	$3,397,539	$7,087,668	$1,532,729

THE AMERICAN SOCIETY OF GENE & CELL THERAPY